Realize non-pharmacological home treatment of depression, treating over 20,000 patients, it has received FDA breakthrough device designation

According to the World Health Organization, depression is one of the leading causes of disability globally, affecting around 264 million people of all ages, with a significant proportion among young people aged 18-25. It is estimated that this disease causes annual losses of up to 1 trillion US dollars.
Currently, common treatment options for depression include antidepressant medication and psychotherapy, but both have certain limitations. Antidepressants take a long time to take effect and may cause side effects such as dry mouth and gastrointestinal discomfort. Long-term use of antidepressants can lead to dependence, and withdrawal symptoms such as headaches, dizziness, and mood swings may occur when stopping the medication. On the other hand, psychotherapy faces challenges such as ensuring patient compliance, instability in effectiveness, limited effectiveness for severe cases, and high costs.
To address the unmet clinical needs in the field of depression treatment, Sooma has entered the field. Founded in 2013, Sooma is a Finnish medical innovation company that has developed a novel treatment for depression aimed at providing a flexible, simple, convenient, and affordable treatment option for patients with inadequate drug treatment effectiveness or limited psychotherapy opportunities.
Precise control of stimulus dose and target, independent home use after one guidance session.
Our brain function depends on the transmission of electrical signals. When people experience depression, these signals become imbalanced in certain areas of the brain. These brain regions are located in the dorsolateral prefrontal cortex (DLPFC). Research indicates that for patients with depression, there is reduced activity in the left DLPFC and excessive activity in the right DLPFC.
Sooma’s depression therapy specifically targets these areas to alleviate depressive symptoms. The therapy uses transcranial direct current stimulation (tDCS) technology and the company’s Class 2 medical device Sooma tDCS for treatment. tDCS uses mild electrical currents to stimulate the brain and alleviate depressive symptoms without the need for medication treatment. By delivering weak electrical currents through two electrodes in a cap, the system stimulates activity near the left electrode while reducing activity near the right electrode. This process helps restore balance between these two brain regions, thereby reducing depressive symptoms.
This solution follows three key principles: the ability to control stimulus dose, precise stimulus targeting, and patients’ ability to self-administer the stimulus.